Aimmune Therapeutics Inc AIMT:NASDAQ

Last Price$16.30Cboe Real-Time Last Sale as of 9:30AM ET 7/13/20
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.62(3.95%)
Bid (Size)$15.86 (100)
Ask (Size)$16.10 (100)
Day Low / High$16.30 - 16.30
Volume3.0 K
  • Latest Stories
  • Commentary and Analysis
Analyst Actions: Cowen Starts Aimmune Therapeutics at Outperform With $35 Price Target
13 minutes ago, 9:23AM ET 7/13/2020 MT Newswires

Aimmune Therapeutics (AIMT) has an average buy rating among analysts, with an average price target of $40. (MT Newswires covers equity, commodity and...

Insider Trends: Insider at AIMSI Technologies Disposes of Shares for Tax Slowing 90-Day Buy Trend
5:08PM ET 6/26/2020 MT Newswires

Dr Jayson Donald Alexander Dallas, Director and President & CEO, reported a sale of 7,907 shares of AIMSI Technologies (AIMT) for approximately $139,321 to...

Insider Trends: Insider at Aimmune Therapeutics Disposes of Shares for Tax Slowing 90-Day Buy Trend
5:08PM ET 6/26/2020 MT Newswires

Dr Jayson Donald Alexander Dallas, Director and President & CEO, sold 7,907 shares of Aimmune Therapeutics (AIMT) for approximately $139,321 to meet tax...

Aimmune Therapeutics Reports Positive Data From Study of Peanut Allergy Treatment; Shares Rise
9:08AM ET 6/08/2020 MT Newswires

Aimmune Therapeutics (AIMT) said Monday that new two-year data suggest the long-term effectiveness of daily treatment with Palforzia in patients with...

Analyst Actions: Credit Suisse Cuts Aimmune Therapeutics PT to $19 From $29 as Palforzia Launch on Hold Due to COVID-19, Maintains Neutral Rating
9:55AM ET 5/13/2020 MT Newswires

Aimmune Therapeutics' (AIMT) average rating among analysts is a buy, with an average price target of $41. Price: 16.92, Change: -0.09, Percent Change:...

--Analyst Actions: RBC Cuts Price Target on Aimmune Therapeutics to $52 From $54 on Delayed Palforzia Launch in the US; Maintains Outperform/Speculative Risk
10:10AM ET 5/12/2020 MT Newswires

Price: 17.41, Change: -0.49, Percent Change: -2.74 ...

Insider Trends: Insider Buying Continued with Purchase of AIMSI Technologies Stock
4:48PM ET 4/24/2020 MT Newswires

Nestle Health Science US Holdings, Inc., 10% Owner, on Feb 26, 2018, made a purchase of 4,175,029 shares in AIMSI Technologies (AIMT) for $128,000,003. ...

Insider Trends: Aimmune Therapeutics Insider 90-Day Buying Trend Prolonged with Purchase
4:48PM ET 4/24/2020 MT Newswires

Nestle Health Science US Holdings, Inc., 10% Owner, purchased 4,175,029 shares in Aimmune Therapeutics (AIMT) for $128,000,003 on Feb 26, 2018. Nestle...

Insider Trends: Insider Buying Extended with Purchase of AIMSI Technologies Stock
5:05PM ET 3/19/2020 MT Newswires

Patrick G Enright, Director, made a purchase of 125,000 shares in AIMSI Technologies (AIMT) on Mar 17, 2020, for $1,420,045. After the Form 4 filing with...

Insider Trends: Insider Purchase Adds to Aimmune Therapeutics Positive Trend
5:05PM ET 3/19/2020 MT Newswires

Patrick G Enright, Director, on Mar 17, 2020, executed a purchase for 125,000 shares in Aimmune Therapeutics (AIMT) for $1,420,045. Enright has control...